KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Cash from Investing Activities (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Cash from Investing Activities for 13 consecutive years, with $62.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 36.35% to $62.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $218.0 million, a 32.12% increase, with the full-year FY2025 number at $218.0 million, up 32.12% from a year prior.
  • Cash from Investing Activities was $62.7 million for Q4 2025 at Xenon Pharmaceuticals, up from $38.5 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $109.2 million in Q2 2024 to a low of -$239.8 million in Q4 2023.
  • A 5-year average of -$13.4 million and a median of $11.9 million in 2021 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: plummeted 1943.03% in 2023, then surged 7637.15% in 2025.
  • Xenon Pharmaceuticals' Cash from Investing Activities stood at -$215.4 million in 2021, then skyrocketed by 94.55% to -$11.7 million in 2022, then tumbled by 1943.03% to -$239.8 million in 2023, then surged by 141.08% to $98.5 million in 2024, then crashed by 36.35% to $62.7 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Cash from Investing Activities are $62.7 million (Q4 2025), $38.5 million (Q3 2025), and $82.3 million (Q2 2025).